The market rally was led by companies overcoming regulatory barriers in regenerative medicine and those tied to a global blockbuster drug candidate most notably SamjinPharm, ChaVaccineInstitute and Lameditech.
These three companies hit their daily upper price limits, fueled by their respective growth momentum. The primary catalyst was AriBio’s announcement of a $4.7 billion (approx. 7 trillion won) technology export deal for its Alzheimer’s treatment, which cast a bright spotlight on its strategic partners and affiliates.
Samjin Pharm trend on May 14.(Image=Naver Finance)
◇Samjin Pharm, The ‘AriBio Effect’ 5.9% Stake Highlights Strategic Alliance
According to KG Zeroin MP Doctor, Samjin Pharm closed at 23,250 won, up 29.9% from the previous trading day, hitting the daily upper limit.
The surge was directly triggered by the news that its partner, AriBio, signed an exclusive global licensing agreement with China’s Fosun Pharma for AR1001, an oral Alzheimer’s treatment, in a deal worth up to $4.7 billion.
Investors noted that the valuation of the Chinese deal significantly exceeds previous domestic contracts validating Samjin Pharm’s "foresight" and raising expectations for future royalty revenue. Market analysts view this not merely as a thematic rally but as a fundamental strengthening of the company’s outlook as the drug approaches commercialization.
Samjin Pharm a traditional pharmaceutical leader with a strong presence in central nervous system (CNS) and circulatory diseases solidified its "blood alliance" with AriBio through a 30 billion won mutual shareholding agreement in 2022.
Currently Samjin Pharm holds a 5.9% stake in AriBio making it the second largest shareholder after Sorlux (14.49%). Conversely AriBio holds an 8.34% stake in Samjin Pharm.
Beyond equity ties the two companies are engaged in substantial R&D cooperation. Samjin Pharm previously secured the domestic manufacturing and distribution rights for AR1001 in a 100 billion won deal and is currently leading the joint domestic clinical trials for the drug.
With the global Phase 3 (POLARIS-AD) topline results expected later this year, the market is pricing in the long-term value of Samjin Pharm’s priority rights and the appreciation of its equity holdings.
"As the value of AriBio’s pipeline is proven globally Samjin Pharm holding a stake of over 5%—is naturally seeing a surge in market expectations." a Samjin Pharm official commented.
Cha Vaccine Institute trend on May 14.(Image=Naver Finance)
◇Cha Vaccine Institute Synergy Expectations Explode Following Sorlux Acquisition
Cha Vaccine Institute also hit the daily limit, jumping 29.9% to close at 3,710 won. The rally was fueled by AriBio’s success and the anticipation of R&D synergies within the newly formed Sorlux-AriBio-Cha Vaccine Institute corporate structure.
Cha Vaccine Institute is an R&D focused firm specializing in next-generation vaccines and immunotherapies based on its proprietary immune enhancement platform. In March, Sorlux—AriBio’s largest shareholder acquired the management rights of Cha Vaccine Institute from CHA Biotech, bringing it into the AriBio ecosystem.
Recently, Cha Vaccine Institute entered a strategic R&D alliance by acquiring 2.8 billion won in AriBio’s convertible bonds (CB) for joint vaccine development. The market expects significant pipeline expansion by combining Cha Vaccine’s platform with AriBio’s drug development expertise. Speculation regarding a future merger or a name change to "AriBio Research Institute" has further stimulated investor sentiment.
"Sorlux and AriBio are showing a strong commitment to using Cha Vaccine Institute as a core pillar for their biotech expansion, rather than just a simple acquisition," an industry insider noted.
Lameditech trend on May 14.(Image=Naver Finance)
◇Lameditech, New Growth Engine in Regenerative Medicine via Tissue Bank Approval
Lameditech joined the rally, surging 29.8% to 6,010 won. The jump followed an official announcement that the company obtained a "Human Tissue Bank" license from the Ministry of Food and Drug Safety (MFDS). This approval provides the legal foundation for Lameditech to expand into the regenerative medicine market using ECM (Extracellular Matrix) materials.
Known for its proprietary ultra miniature high power laser technology, Lameditech has focused on aesthetic and medical devices. Under current regulations human derived materials like ECM are classified as "human tissue" rather than medical devices making a tissue bank license a prerequisite for entry.
The company is developing an integrated solution that combines its Laser Drug Delivery System (DDS) technology with ECM materials. By creating micro channels in the skin via laser to deliver ECM, the company aims to enhance the efficiency of regenerative treatments. This move signifies a shift from equipment sales to a recurring revenue model through bio material consumables.
"The tissue bank approval is a critical turning point for us to transition from a laser device company to a regenerative medicine materials provider."
a company official stated "We will secure new growth engines by combining our laser DDS technology with ECM bio materials."
